Dyne Therapeutics is advancing z-rostudirsen toward approval for DMD after data showed increased dystrophin and early functional trends.

Dyne Therapeutics started the new year with proof-of-concept clinical data for experimental genetic medicines addressing two rare muscle diseases—one of which has no FDA-approved treatments. Now the ...

On Tuesday, Dyne Therapeutics Inc. (NASDAQ:DYN) announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 ...

Shares of Dyne Therapeutics (NASDAQ:DYN) plunged 23% after the biotech firm announced changes to its regulatory strategy for DYNE-101, a treatment for myotonic dystrophy type 1 (DM1), following a ...

Monday, Dyne Therapeutics Inc (NASDAQ:DYN) released clinical data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its ongoing Phase 1/2 ...

Shares of Dyne Therapeutics fell on Tuesday after the company revised the primary endpoint in the registrational expansion cohort of its Achieve trial for DYNE-101, a treatment for myotonic dystrophy ...

The last time I wrote about Dyne Therapeutics (DYN) it was with respect to a Seeking Alpha article entitled "Dyne: H2 2024 Muscle Disease Data Could Boost Value". In this article, I noted about the ...

The last time I wrote about Dyne Therapeutics (DYN) it was with respect to a Seeking Alpha article entitled "Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker". With ...

- Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late 2025 - In addition to DYNE-251, Dyne is ...

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday. Shares of Aehr Test Systems (NASDAQ:AEHR) fell sharply during Monday’s session after the company reported ...